BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 29510685)

  • 1. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.
    Ramadori G; Bosio P; Moriconi F; Malik IA
    BMC Cancer; 2018 Mar; 18(1):257. PubMed ID: 29510685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
    Obed A; Bashir A; Jarrad A
    Am J Case Rep; 2016 Sep; 17():672-5. PubMed ID: 27647003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
    Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
    Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patient with hepatitis C-related cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy.
    Shibata M; Yanaga K; Morizane T; Yanagawa T; Hirakawa M; Ueno Y; Esquivel CO; Mitamura K
    J Gastroenterol; 2003; 38(6):598-602. PubMed ID: 12858850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
    Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
    Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
    Willuweit K; Canbay A; Gerken G; Timm J; Paul A; Treckmann J; Herzer K
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):55-61. PubMed ID: 27824245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of recurrent hepatitis C virus after liver transplantation.
    Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
    World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy.
    Eurich D; Boas-Knoop S; Bahra M; Neuhaus R; Somasundaram R; Neuhaus P; Neumann U; Seehofer D
    Transplantation; 2012 Mar; 93(6):644-9. PubMed ID: 22411462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
    Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of hepatitis C virus infection after liver transplantation.
    Böker KH; Dalley G; Bahr MJ; Maschek H; Tillmann HL; Trautwein C; Oldhaver K; Bode U; Pichlmayr R; Manns MP
    Hepatology; 1997 Jan; 25(1):203-10. PubMed ID: 8985291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.